Bufotenin (Tryptamine · Serotonergic Psychedelic · Research Reference)

Compound	Bufotenin (5-Hydroxy-N,N-dimethyltryptamine; Bufotenine; 5-OH-DMT)
Class	Alkaloid — Tryptamine (Indole)
CAS	487-93-4
Molecular formula	C₁₂H₁₆N₂O
Primary sources	Anadenanthera colubrina (vilca/cebil seeds), Anadenanthera peregrina (yopo seeds), Bufo alvarius toad parotoid glands (non-plant source)
Plant part	Seeds, seed pods
Claim strength	Emerging
Key applications	Psychedelic research; cardiovascular pharmacology reference; tryptamine chemistry; informational-only
Buy from Herbuno	Informational reference — see HerbIQ Compound Index →

Name origin: Bufotenin is named after Bufo (the toad genus) — it was first isolated from the skin secretions of Bufo vulgaris (European common toad) before being identified in Anadenanthera seeds. The 5-hydroxy group on the indole ring distinguishes it from DMT (no 5-substituent) and 5-MeO-DMT (5-methoxy). Traditional use: Bufotenin is the primary psychoactive alkaloid in yopo (Anadenanthera peregrina seeds, used by indigenous peoples of the Orinoco basin as insufflated snuff) and vilca/cebil (A. colubrina seeds, used in Andean ceremonial contexts). Archaeological evidence of yopo use in South America dates to at least 4,000 years ago (pipe inhalation artefacts from Chile and Argentina). These are among the oldest documented psychedelic practices. Research trajectory: Bufotenin's psychedelic status was historically disputed — early human studies (Fabing & Hawkins 1956) used IV injection producing primarily cardiovascular effects with questionable psychedelic responses, leading to debate about CNS penetration. Modern reassessment using intranasal administration (replicating traditional route) confirms psychedelic activity. Bufotenin has lower blood-brain barrier permeability than DMT due to its polar 5-OH group; the traditional snuff preparations likely achieve CNS effect partly through peripheral mechanisms and partly through limited CNS penetration. Safety context: Bufotenin is a Schedule I controlled substance in the US and similarly controlled in most jurisdictions. At high IV doses, it produces significant cardiovascular stimulation (tachycardia, hypertension, flushing) — the primary toxicological concern.

---

Research Profile of Bufotenin

Serotonergic pharmacology: Bufotenin is a potent 5-HT2A and 5-HT2C agonist — the same mechanistic targets as DMT, psilocin, and LSD. Its 5-hydroxyl group increases polarity, reducing CNS penetration relative to DMT, but sufficient CNS effect occurs via traditional insufflation routes. Sigma-1 receptor activity has also been characterised. Claim strength: Moderate (mechanistic).

Cardiovascular effects: IV bufotenin produces pronounced cardiovascular stimulation — tachycardia, hypertension, and facial flushing — mediated via peripheral serotonin receptor activation on vascular smooth muscle. These effects, prominent in early IV studies, are substantially less marked with intranasal administration at equivalent psychedelic doses. Claim strength: Moderate (pharmacological).

Psychedelic activity: Modern intranasal studies with synthetic bufotenin and traditional yopo snuff consumption demonstrate visual hallucinations, altered time perception, and synesthesia consistent with other tryptamine psychedelics. The psychedelic profile is similar to DMT but of shorter onset and with greater peripheral cardiovascular component. Claim strength: Emerging (limited human data).

Endogenous presence: Bufotenin has been detected in human urine — historically used as a proposed marker of schizophrenia in early psychiatry research (since revised; urinary bufotenin detection is now attributed to non-psychotic serotonin metabolism in certain dietary contexts). It is also produced endogenously via N-methylation of 5-hydroxytryptamine (serotonin) by INMT, though at low physiological concentrations. Claim strength: Emerging.

---

Regulatory and Research Context

Bufotenin is Schedule I (US), similarly controlled internationally. Anadenanthera peregrina and A. colubrina seeds are legal as botanical specimens in some jurisdictions; controlled in others. The toad-secretion source (Bufo alvarius / Incilius alvarius parotoid glands) produces 5-MeO-DMT as the dominant compound with minor bufotenin — a separate entry covers 5-MeO-DMT.

No supplement or nutraceutical application exists. Traditional yopo snuff is not a commercial product. Research use requires controlled substance licences in all major jurisdictions.

The cardiovascular risk profile of bufotenin (especially by IV or high-dose routes) distinguishes it from psilocybin and DMT in clinical risk assessment. Intranasal or traditional insufflation routes have a better safety profile but still require supervised clinical settings for research purposes.

This entry documents bufotenin as part of the HerbIQ tryptamine alkaloid series for completeness of the psychedelic plant alkaloid reference library.

---

Frequently Asked Questions — Bufotenin

What distinguishes bufotenin from N,N-DMT structurally and pharmacologically?
Bufotenin carries a 5-hydroxyl group on the indole ring; DMT has no substituent at C-5. The hydroxyl group increases polarity and reduces blood-brain barrier penetration — explaining why bufotenin produces more peripheral cardiovascular effects relative to its central psychedelic effects compared to DMT. Both are potent 5-HT2A agonists; bufotenin requires higher doses for equivalent psychedelic effect due to CNS bioavailability limitations.

Is the Bufo alvarius toad the same source as bufotenin?
No — Bufo alvarius (Sonoran Desert toad, now Incilius alvarius) parotoid glands secrete primarily 5-MeO-DMT (up to 15% dry weight), not bufotenin. Bufotenin is found in small amounts in Bufo bufo (European common toad) and related species — from which it was originally named — but the Sonoran Desert toad phenomenon in contemporary psychedelic culture relates to 5-MeO-DMT, not bufotenin.

What is yopo and what was its traditional ceremonial role?
Yopo is a traditional psychoactive snuff made from the seeds of Anadenanthera peregrina, roasted and ground, then insufflated through bird-bone or bamboo tubes in ceremonial contexts by indigenous peoples of the Orinoco river basin. Seeds contain primarily bufotenin (up to 7.4%) with minor DMT and 5-MeO-DMT. Archaeological evidence of yopo use dates to at least 4,000 years in South America, making it one of the oldest documented psychedelic rituals.

Why was bufotenin historically proposed as a schizophrenia biomarker?
In the 1950s–1970s, elevated urinary bufotenin was proposed as a biochemical marker of schizophrenia based on the transmethylation hypothesis — the idea that aberrant methylation of serotonin metabolites to endogenous psychedelics might cause psychosis. Subsequent controlled studies showed that urinary bufotenin elevations in some schizophrenia patients were attributable to dietary factors and analytical artefacts rather than endogenous psychedelic production. The transmethylation hypothesis fell out of favour but contributed to endogenous tryptamine research.

Related compounds: N,N-DMT, 5-MeO-DMT, Serotonin, Harmine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery